Posted by Michael Wonder on 25 Sep 2024
Trifluridine with tipiracil hydrochloride in combination with bevacizumab for the treatment of patients with metastatic colorectal cancer after two systemic treatments (final guidance)
25 September 2024 - NICE has published final evidence-based recommendations on the use of trifluridine with tipiracil hydrochloride (Lonsurf) for use in combination with bevacizumab for the treatment of adults with metastatic colorectal cancer after two systemic treatments.
Trifluridine with tipiracil hydrochloride, when used in combination with bevacizumab, is recommended for the treatment of adults with metastatic colorectal cancer who have had two lines of treatment (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, vascular endothelial growth factor (VEGF) inhibitors or epidermal growth factor receptor (EGFR) inhibitors).
Trifluridine with tipiracil hydrochloride and bevacizumab is only recommended if Servier provides trifluridine with tipiracil hydrochloride according to the commercial arrangement.
